Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Adenocarcinoma Metastatic × IFL protocol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 73 Colonic Neoplasms 17 Neoplasm Metastasis 15 Rectal Neoplasms 13 Neoplasms 9 Stomach Neoplasms 6 Carcinoma, Non-Small-Cell Lung 4 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Gastrointestinal Neoplasms 3 Carcinoma, Renal Cell 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Carcinoma, Neuroendocrine 2 Breast Neoplasms 2 Adenocarcinoma 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Ras-mutated Metastatic Colorectal Cancer 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Adenocarcinoma Metastatic 1 Neuroendocrine Tumors 1

Interventions

spartalizumab 1 sapropterin 1 penpulimab 1 niraparib 1 anlotinib 1 Taxes 1 Leucovorin 1 Ipilimumab 1 IFL protocol 1 Gemcitabine 1 Decitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06747845 2025-09-16

ParpVax2

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡